Autolus Therapeutics
AUTL
121 hedge funds and large institutions have $1.12B invested in Autolus Therapeutics in 2024 Q1 according to their latest regulatory filings, with 28 funds opening new positions, 46 increasing their positions, 27 reducing their positions, and 6 closing their positions.
367% more first-time investments, than exits
New positions opened: 28 | Existing positions closed: 6
91% more call options, than puts
Call options by funds: $1.19M | Put options by funds: $625K
70% more repeat investments, than reductions
Existing positions increased: 46 | Existing positions reduced: 27
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
50% more capital invested
Capital invested by funds: $747M → $1.12B (+$374M)
22% more funds holding
Funds holding: 99 → 121 (+22)
0.57% less ownership
Funds ownership: 66.67% → 66.1% (-0.57%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACA
Avoro Capital Advisors
New York
|
+$77M |
| 2 |
Wellington Management Group
Boston,
Massachusetts
|
+$67.1M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$56.2M |
| 4 |
DM
Deerfield Management
New York
|
+$22.7M |
| 5 |
DTC
Deep Track Capital
Greenwich,
Connecticut
|
+$21.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
PBA
Paradigm Biocapital Advisors
New York
|
-$38.6M |
| 2 |
Adage Capital Partners
Boston,
Massachusetts
|
-$3.9M |
| 3 |
TAM
TFG Asset Management
Grand Cayman,
Cayman Islands
|
-$2.96M |
| 4 |
LCM
Lynx1 Capital Management
San Juan,
Puerto Rico
|
-$2.92M |
| 5 |
UOC
UBS O'Connor
Chicago,
Illinois
|
-$2.39M |
AUTL Hedge Fund Activity: Q1 2024 in Review
121 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Autolus Therapeutics (AUTL) for Q1 2024, worth a combined $1.12B — up 50% from $747M a quarter earlier.
Buyers outnumbered sellers: 28 funds opened new AUTL positions and 6 closed out — a net gain of 22 holders — while 46 added to existing stakes and 27 trimmed.
The largest buyer was Avoro Capital Advisors, opening a new position worth an estimated $77M. The largest seller was Paradigm Biocapital Advisors, cutting an estimated $38.6M.
- 121 institutional investors held Autolus Therapeutics (AUTL) as of Q1 2024, up from 99 in Q4 2023.
- Funds reported $1.12B of Autolus Therapeutics stock for Q1 2024, up 50% quarter-over-quarter.
- 28 funds opened new Autolus Therapeutics positions in Q1 2024 and 6 closed out, a net change of +22 holders.
- The largest Autolus Therapeutics buyer in Q1 2024 was Avoro Capital Advisors, an estimated $77M added.
- The largest Autolus Therapeutics seller in Q1 2024 was Paradigm Biocapital Advisors, an estimated $38.6M sold.
Based on aggregated 13F filings for Q1 2024.